{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:20:14Z","timestamp":1787930414369,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Central Universities Young Talent Support Program, Class A","award":["lzujbky-2025-ytA07"],"award-info":[{"award-number":["lzujbky-2025-ytA07"]}]},{"name":"the Provincial Talent (Young Team) Program of the Organization Department of the CPC Gansu Provincial Committee","award":["2025QNTD18"],"award-info":[{"award-number":["2025QNTD18"]}]},{"name":"the General Project of the Joint Fund of the Gansu Provincial Department of Science and Technology","award":["25JRRA1267"],"award-info":[{"award-number":["25JRRA1267"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05316-9","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:32:01Z","timestamp":1787927521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bladder preservation with disitamab vedotin plus PD-1 inhibitors and local intensification in muscle-invasive bladder cancer: a single-center retrospective cohort of 81 patients"],"prefix":"10.1007","author":[{"given":"Yan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruonan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqiu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenbao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjin","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"1","key":"5316_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/JU.0000000000003981","volume":"212","author":"J Holzbeierlein","year":"2024","unstructured":"Holzbeierlein J et al (2024) Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024). J Urol 212(1):3\u201310","journal-title":"J Urol"},{"issue":"5","key":"5316_CR2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden AG et al (2025) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines. Eur Urol 87(5):582\u2013600","journal-title":"Eur Urol"},{"issue":"3","key":"5316_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2021.09.018","volume":"81","author":"MB Clements","year":"2022","unstructured":"Clements MB et al (2022) Health-related quality of life for patients undergoing radical cystectomy: results of a large prospective cohort. Eur Urol 81(3):294\u2013304","journal-title":"Eur Urol"},{"issue":"1","key":"5316_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eururo.2025.03.017","volume":"89","author":"S Gupta","year":"2026","unstructured":"Gupta S et al (2026) Bladder preservation strategies in muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. Eur Urol 89(1):18\u201328","journal-title":"Eur Urol"},{"issue":"1","key":"5316_CR5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00345-024-05196-7","volume":"42","author":"E Kaufmann","year":"2024","unstructured":"Kaufmann E et al (2024) Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review. World J Urol 42(1):527","journal-title":"World J Urol"},{"issue":"1","key":"5316_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102229","volume":"23","author":"NV Kotha","year":"2025","unstructured":"Kotha NV et al (2025) Patterns of failure after definitive trimodality therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 23(1):102229","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"5316_CR7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41585-024-00872-0","volume":"21","author":"G Roviello","year":"2024","unstructured":"Roviello G et al (2024) The evolving treatment landscape of metastatic urothelial cancer. Nat Rev Urol 21(10):580\u2013592","journal-title":"Nat Rev Urol"},{"issue":"1","key":"5316_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","volume":"21","author":"R Nadal","year":"2024","unstructured":"Nadal R et al (2024) Progress in systemic therapy for advanced-stage urothelial carcinoma. Nat Rev Clin Oncol 21(1):8\u201327","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"5316_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T et al (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390(10):875\u2013888","journal-title":"N Engl J Med"},{"issue":"7","key":"5316_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41585-024-00858-y","volume":"21","author":"M Santoni","year":"2024","unstructured":"Santoni M et al (2024) Pembrolizumab plus enfortumab vedotin in urothelial cancer. Nat Rev Urol 21(7):387\u2013388","journal-title":"Nat Rev Urol"},{"issue":"1","key":"5316_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41698-025-01211-1","volume":"10","author":"X Guo","year":"2025","unstructured":"Guo X et al (2025) Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study. npj Precis Oncol 10(1):11","journal-title":"npj Precis Oncol"},{"issue":"11","key":"5316_CR12","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky MD et al (2023) Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med 29(11):2825\u20132834","journal-title":"Nat Med"},{"issue":"1","key":"5316_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s00345-025-05544-1","volume":"43","author":"JM Yao","year":"2025","unstructured":"Yao JM et al (2025) Efficacy and safety of disitamab vedotin in combination with immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma. World J Urol 43(1):154","journal-title":"World J Urol"},{"issue":"12","key":"5316_CR14","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1007\/s11255-025-04567-2","volume":"57","author":"S Zhang","year":"2025","unstructured":"Zhang S et al (2025) A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)-based on real-world data analysis. Int Urol Nephrol 57(12):3993\u20134001","journal-title":"Int Urol Nephrol"},{"issue":"8","key":"5316_CR15","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","volume":"25","author":"C Lynch","year":"2024","unstructured":"Lynch C et al (2024) Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol 25(8):e352\u2013e362","journal-title":"Lancet Oncol"},{"issue":"5","key":"5316_CR16","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.chembiol.2025.04.001","volume":"32","author":"E Guilbaud","year":"2025","unstructured":"Guilbaud E et al (2025) Impact of radiation therapy on the immunological tumor microenvironment. Cell Chem Biol 32(5):678\u2013693","journal-title":"Cell Chem Biol"},{"key":"5316_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104270","volume":"195","author":"S Natangelo","year":"2024","unstructured":"Natangelo S et al (2024) Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates. Crit Rev Oncol Hematol 195:104270","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"5316_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero P et al (2024) European Association of Urology Guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update. Eur Urol 86(6):531\u2013549","journal-title":"Eur Urol"},{"issue":"4","key":"5316_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM et al (2024) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol 211(4):533\u2013538","journal-title":"J Urol"},{"key":"5316_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1562260","volume":"15","author":"R Zhang","year":"2025","unstructured":"Zhang R, Ke CX (2025) Advances in bladder preservation therapy for muscle-invasive bladder cancer. Front Oncol 15:1562260","journal-title":"Front Oncol"},{"issue":"6","key":"5316_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067634","volume":"13","author":"U Petrausch","year":"2023","unstructured":"Petrausch U et al (2023) Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06\/19). BMJ Open 13(6):e067634","journal-title":"BMJ Open"},{"key":"5316_CR22","unstructured":"Association, T.P.C.o.C.A.-C. et al. (2021) [Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China]. Zhonghua Zhong Liu Za Zhi. 43 (10): 1001\u20131006."},{"key":"5316_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050894","author":"PH Chang","year":"2024","unstructured":"Chang PH et al (2024) Effect of clinical complete remission following neoadjuvant pembrolizumab or chemotherapy in bladder-preservation strategy in patients with muscle-invasive bladder cancer declining definitive local therapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16050894","journal-title":"Cancers (Basel)"},{"key":"5316_CR24","doi-asserted-by":"publisher","first-page":"S1138","DOI":"10.1016\/j.annonc.2024.08.2052","volume":"35","author":"MD Galsky","year":"2024","unstructured":"Galsky MD et al (2024) 1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la\/mUC): RC48G001 cohort C. Ann Oncol 35:S1138\u2013S1139","journal-title":"Ann Oncol"},{"key":"5316_CR25","doi-asserted-by":"publisher","first-page":"1719978","DOI":"10.3389\/fcell.2025.1719978","volume":"13","author":"A Di Spirito","year":"2025","unstructured":"Di Spirito A et al (2025) Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies. Front Cell Dev Biol 13:1719978","journal-title":"Front Cell Dev Biol"},{"key":"5316_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1591379","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y et al (2025) Immunotherapeutic strategies for invasive bladder cancer: a comprehensive review. Front Immunol 16:1591379","journal-title":"Front Immunol"},{"issue":"4","key":"5316_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1158\/1078-0432.CCR-24-2636","volume":"31","author":"X Garcia-Del-Muro","year":"2025","unstructured":"Garcia-Del-Muro X et al (2025) Bladder preservation with Durvalumab plus Tremelimumab and concurrent radiotherapy in patients with localized muscle-invasive bladder cancer (IMMUNOPRESERVE): a phase II Spanish Oncology GenitoUrinary Group trial. Clin Cancer Res 31(4):659\u2013666","journal-title":"Clin Cancer Res"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05316-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05316-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05316-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:32:03Z","timestamp":1787927523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05316-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":27,"alternative-id":["5316"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05316-9","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of Lanzhou University Second Hospital (Approval No. 2026A-097). All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for written informed consent was waived by the Ethics Committee of Lanzhou University Second Hospital because of the retrospective nature of the study and the use of de-identified data.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}